
A study on medicine shortages in the Netherlands found that disease and costs were the two most affected elements, with 30% and 20% of shortages rated high on these elements, respectively. The study used a framework of economic, clinical, and patient outcomes to assess the impact of medicine shortages on patients. Direct impact, represented by alternative product and disease, was rated high for 30% of the shortages, while indirect impact, represented by costs, susceptibility, and number of patients, was rated high for 17% of the shortages. No significant differences in impact scores were found based on product characteristics.
Recent Posts
AI Governance Pharmaceuticals: Ensuring Ethical AI Integration in the Medicines Lifecycle
In the pharmaceutical industry, AI governance in pharmaceuticals is crucial for harnessing artificial intelligence's potential in drug discovery, clinical trials, and patient monitoring. How can pharma companies integrate AI ethically across the medicines lifecycle? This article draws on a recent...
2025 China Drug Catalog Boosts Access with 114 New Drugs and Innovative Solutions
Expansion of Coverage in the 2025 National Basic Medical Insurance Drug Catalog
In this update we highlight updates and implications of the 2025 National Basic Medical Insurance Drug Catalog in China's ...
NICE Approves Seven Digital Cardiac Rehabilitation Technologies for Enhanced Patient Care
Digital cardiac rehabilitation is transforming how patients with cardiovascular disease access vital recovery support, and if you're wondering about the latest NICE recommendations for digital platforms in cardiac rehab, here's the key update. NICE has conditionally approved seven innovative tool...